François-Ludovic Sauvage is a Researcher at the University of Limoges within the Faculty of Medicine and Pharmacy and Department of Pharmacology and Toxicology . His research focuses on peptidomics , proteomics , pharmacokinetic modeling , and biomarker discovery for transplantation medicine. Education: Engineer in Chemistry & Master’s in Analytical Chemistry from École Nationale Supérieure de Chimie de Mulhouse Affiliations: INSERM Unit (member since 2007), CHU de Limoges His analytical chemistry expertise drives studies on drug metabolism, protein modifications, and transporter dynamics. Publications highlight LC-MS applications in transplantation toxicology , renal pharmacokinetics , and biomarker validation . Current work explores multi-omics integration for personalized immunosuppressive therapy. Key collaborations include European Biomargin program contributions and technical innovations in LC-MS for clinical monitoring , cell line modeling , and metabolomic profiling . No formal awards or advisees are documented in available sources.
Donna Dare is an Assistant Professor in the Department of Clinical Pharmacy at the University of California San Francisco and serves as Associate Dean at the San Francisco Veterans Affairs Medical Center. She also directs the Pharmacy Service at SFVAMC, focusing on administrative support, mentoring, and clinical research. Affiliations: University of California San Francisco San Francisco Veterans Affairs Medical Center Her research centers on Medication Safety , Clinical Decision Support Systems , and Drug Interaction Management within ambulatory care settings. Key study areas include electronic health record design, prescriber behavior, and institutional guideline adherence. Scientific contributions include publications on drug-drug interaction alert overrides in ambulatory care environments (2007) and practitioner perspectives on computerized alerts in VA systems (2007). These works examine Healthcare Informatics challenges and Medical Order Entry System optimization. Scientific Recognition Fellow, California Society of Health-System Pharmacists (2011)
Valerie Clinard serves as Associate Dean of Experiential Education and Professional Development at the University of California San Francisco School of Pharmacy. She holds a Professor position in the Department of Clinical Pharmacy and oversees both Introductory Pharmacy Practice Experience (IPPE) and Advanced Pharmacy Practice Experience (APPE) programs. PharmD, University of North Carolina at Chapel Hill (2000) PGY1 Residency in Community-Based Pharmacy, Campbell University College of Pharmacy at Kerr Drug, Inc. (2001) Her research focuses on experiential education , pharmacy education , and transitions of care . She contributes to curriculum transformation initiatives and implements innovative pharmacy practice experiences. Her work examines pharmacist roles in chronic disease management , toxicology , and warfarin therapy . Key scientific recognitions include: 2019-2020 Annual Teaching Awards 2020 Recognition for Educational Contributions 2016 Troy C. Daniels Awards for Curricular Transformation Clinard leads preceptor development programs and collaborates with UCSF Medical Center teams. She maintains active involvement in the UCSF Academy of Medical Educators and contributes to national pharmacy education standards.
Dr. Ryan Hernandez is a Professor at the University of California San Francisco (UCSF) , affiliated with the Department of Bioengineering and Therapeutic Sciences . He co-leads the Torgerson-Hernandez Lab (THeLab) and serves as Co-Director of multiple training programs including the Biological and Medical Informatics Graduate Program (BMI) , Genentech-UCSF School of Pharmacy Fellowship Program , and UCSF PREP . PhD in Biometry, Cornell University (2007) MS in Biometry, Cornell University (2003) BA in Mathematics, Pitzer College (2003) His research focuses on human genetic variation using whole-genome sequencing to study disease susceptibility and drug response . Key areas include computational biology , population genetics , and systems pharmacology . Recent publications emphasize admixed populations , metabolomic biomarkers , and genetic simulation tools . Scientific awards include the Sloan Research Fellowship (2013-2016) and Basic Science Award in HIV/AIDS (2014-2015). He also received Outstanding Teaching Assistant recognition from Cornell in 2007.
C. Anthony Hunt is a Professor at the University of California San Francisco (UCSF), affiliated with the School of Pharmacy and the Department of Bioengineering and Therapeutic Sciences . He also maintains external affiliations with F. Hoffmann-La Roche Ltd. and the Office of Clinical Pharmacology (OCP), U.S. Food and Drug Administration . Education : BSc in Applied Biology, Georgia Institute of Technology BSc in Chemistry, Georgia Institute of Technology PhD in Pharmaceutical Sciences, University of Florida Research Interests focus on theoretical systems pharmacology , multiscale modeling , and computational biology to understand causal mechanisms linking molecular changes to organism-level phenotypes. His work emphasizes personalized medicine , biomedical informatics , and therapeutic bioengineering , particularly in drug development and regulatory sciences . Scientific Contributions include developing synthetic modeling methods for mechanistic hypothesis testing in drug metabolism, liver injury, and epithelial cell dynamics. He has published extensively in PLoS Computational Biology , Journal of Pharmacology and Experimental Therapeutics , and BMC Systems Biology , with over 25 years of continuous NIH funding to his research group. Major Awards : American Association for the Advancement of Science (1984) Highest Honors in Chemistry, Georgia Institute of Technology (1970) Laboratory Work involves creating biomimetic computational models of hepatocytes, epithelial cells, and drug transport systems. His team has developed in silico livers , virtual transwell devices , and agent-based frameworks for studying cellular interactions and drug disposition across multiple scales.
M.Sc. Swapnil Awasthi serves as a Doctoral candidate and Research Fellow at the Laboratory for Statistical Genetics within the Department of Psychiatry and Psychotherapy at Charité - University Medicine Berlin since 2016. His work bridges advanced statistical methodologies with psychiatric research to unravel genetic underpinnings of mental illnesses, contributing to the department's mission of developing precision interventions for mental health disorders. His academic foundation includes: Bachelor of Science in Pharmacy from Pranveer Singh Institute of Technology, Kanpur (2007-2011) Master of Science in Life Science Informatics from Rheinische Friedrich-Wilhelms-Universität Bonn (2012-2015) Swapnil's research specializes in applying computational genetics to psychiatric disorders, developing statistical models for genome-wide association studies to identify risk variants for conditions like schizophrenia and depression. His interdisciplinary approach integrates pharmaceutical knowledge with cutting-edge bioinformatics, focusing on translating genetic discoveries into clinically actionable insights for early diagnosis and personalized treatment strategies. As part of Campus Charité Mitte's Department of Psychiatry and Neurosciences, he collaborates within a dynamic ecosystem of over 40 research groups spanning digital therapeutics, neuromodulation, and pharmacological innovation. The department operates across historic Mitte campus and St. Hedwig Hospital locations, integrating 214 inpatient and 121 day clinic services with research to advance mental healthcare through multidisciplinary scientific exploration.
Dr. Emily Aboujaoude is a Clinical Assistant Professor at the Department of Pharmacy Practice, D'Youville University School of Pharmacy. She earned her Doctor of Pharmacy from Lebanese American University in Beirut (2014) and completed PGY1 and PGY2 residencies in Wichita, KS, and Houston, TX, respectively. Her academic journey includes leadership roles in drug information centers and transitioning a residency program to ASHP accreditation. Education: Doctor of Pharmacy, Lebanese American University (2014) PGY1 Pharmacy Residency, Ascension Via Christi Hospitals (2019) PGY2 Medication-Use Safety and Policy Residency, MD Anderson Cancer Center (2020) ASHP/ISMP Online Medication Safety Certificate (2023) Dr. Aboujaoude's research focuses on Medication Safety , Clinical Informatics , and High-Risk Patient Populations , particularly pediatrics and oncology. Her recent publications address antibiotic dosing, neonatal pharmacology, decarbonizing practices, and CAR-T therapy safety. Scientific Awards: No specific awards mentioned. She mentors pharmacy students and residents, emphasizing drug information and medication safety. Her work spans drug development, quality improvement initiatives, and pandemic response strategies.
Joshua Devine, Ph.D., Pharm.D., FAPhA, serves as an Assistant Professor of Public Health in the College of Health Sciences at Des Moines University. With over two decades of federal health leadership experience, he previously held pivotal roles including Regional Health Administrator for the U.S. Department of Health and Human Services (HHS) Region 5, Technical Director at the Centers for Medicare and Medicaid Services (CMS), and economic evaluation leadership for the Department of Defense's $7 billion TRICARE pharmacy program. His academic credentials include: Doctor of Pharmacy (Pharm.D.) from Drake University (2000) Doctor of Philosophy (Ph.D.) in Social, Administrative, and Clinical Pharmacy from the University of Minnesota (2006) Dr. Devine's research spans public health systems , pharmaceutical economics , and health policy , with critical focus on drug shortages (particularly during the COVID-19 pandemic), medication adherence, cardiovascular outcomes, cancer care disparities, and combating health misinformation. His work directly addresses national challenges including drug overdose prevention, infectious disease control, health equity, and mental health infrastructure through data-driven public health frameworks. Analysis of his recent publications reveals a dominant scholarly emphasis on pharmaceutical supply chain vulnerabilities—especially angiotensin receptor blocker and chemotherapy drug shortages—and their real-world clinical impacts across cardiovascular, oncology, and diabetes care domains. His methodology frequently employs retrospective cohort studies and cross-sectional analyses to evaluate policy interventions. His distinguished recognitions include: 2022 Lifetime Achievement Award for Service to the Citizen® 2002 Preceptor of the Year, University of Nebraska Medical Center College of Pharmacy As an educator, Dr. Devine integrates frontline federal health program management experience with academic instruction, emphasizing evidence-based practice and the urgent need for robust public health information ecosystems. He is passionately committed to developing future public health leaders capable of tackling complex health challenges through scientific rigor and innovative policy solutions.
Jeffrey M. Cohen, MD, MPH is an Associate Professor of Dermatology and Biomedical Informatics and Data Science at Yale School of Medicine. He serves as Director of the Psoriasis Treatment Program and Director of Safety in the Dermatology department. Dr. Cohen is board-certified in dermatology and treats the full spectrum of skin conditions with special expertise in immune-mediated disorders like psoriasis and eczema. Dr. Cohen received his MD from Harvard Medical School (2015) and completed dermatology residency at New York University School of Medicine (2019). He earned an MPH from Yale School of Public Health (2025) and completed an internship at Beth Israel Deaconess Medical Center (2016). His educational background reflects a strong foundation in clinical medicine, dermatology, and public health. Dr. Cohen's research focuses on the epidemiology of skin conditions, relationships between skin disorders and systemic medical problems, and healthcare delivery systems in dermatology. His work spans psychodermatology, environmental triggers of skin disease, healthcare disparities, and the application of biomedical informatics to dermatological care. He has published over 150 peer-reviewed articles, with recent work examining connections between skin conditions and neurological, psychiatric, vascular, and oncological disorders. His publication record demonstrates a clear trend toward population health research using large datasets like the NIH All of Us Research Program. Dr. Cohen frequently investigates comorbidities associated with inflammatory skin diseases, particularly examining connections between dermatological conditions and mental health, vascular disease, and other systemic disorders. His recent work also explores healthcare policy issues, environmental factors affecting skin health, and the application of artificial intelligence to dermatological information. 2025 John N. Forrest, Jr., MD Prize for Mentorship in Student Research Castle Connolly Top Doctor 2025 Emerging Generation (E-Gen) Award 2024 Top Doctors Rising Star 2024 2020-2021 Journal of the American Academy of Dermatology Editorial Mentorship Program Dr. Cohen serves in significant editorial and organizational roles, including the Editorial Board of the Journal of the American Academy of Dermatology, Senior Editor for the Journal of Psoriasis and Psoriatic Arthritis, Councilor of the International Psoriasis Council, and Medical Board member of the National Psoriasis Foundation. His collaborative research network spans multiple disciplines, with frequent co-authorship with colleagues in biomedical informatics, psychiatry, and public health. Dr. Cohen also leads initiatives examining collaborative care models between dermatologists and pharmacists for specialty medication management. At Yale, Dr. Cohen directs the Psoriasis Treatment Program and is involved with the Cutaneous Granulomatous Disorders Program and Spondyloarthritis Program. His clinical practice spans Yale Medicine Dermatology offices in New Haven and Branford, where he applies his philosophy of treating each patient like a family member and tailoring treatments to individual needs.
Dr. Sherry Wang is a tenure-track Assistant Professor at Chapman University School of Pharmacy, leading the Research Center for Healthcare AI Initiative. Her interdisciplinary research combines machine learning, epidemiology, clinical pharmacy, health economics, and health services research to improve healthcare delivery and outcomes. Education: China Pharmaceutical University – Bachelor of Science University of Hong Kong – Master of Philosophy The Chinese University of Hong Kong – Ph.D. Her work focuses on optimizing care pathways for chronic diseases and addiction, leveraging real-world data (RWD) to address healthcare access and quality issues, particularly for populations with substance use disorders. She has international experience across Asia, Australia, and the US. Recent scholarly trends show her work spans machine learning (e.g., opioid risk scoring bias), addiction treatment (buprenorphine utilization), and chronic disease management (metabolic syndrome, breast cancer pain). She integrates geospatial analysis and health policy evaluation into her research. Scientific Awards: Recipient of AACP New Investigator Award (2022) Finalist, Women in AI Awards North America – AI Researcher of the Year (2025) CHPAMS and AFLSP Fellowships Dr. Wang mentors graduate students, visiting scholars, undergraduates, and high school students, with one Ph.D. student receiving the James L. Doti Outstanding Graduate Student Award. Her research is funded by NIH’s AIM-AHEAD program, McGovern Foundation, Chapman University, AACP, and CRE2 at Washington University.
Dr. Moom Roosan serves as an Assistant Professor in the Department of Pharmacy Practice at Chapman University School of Pharmacy, a position she has held since June 4, 2018. Her academic appointments place her at the intersection of pharmacy practice, biomedical informatics, and translational research. Dr. Roosan received her Associate of Science in Computer Science from Indiana University and Purdue University at Fort Wayne in 2006, followed by a Doctor of Pharmacy (PharmD) from Purdue University in 2010. She furthered her education with a PhD from the University of Utah School of Medicine in Biomedical Informatics with a focus on genomics and clinical informatics. Her research expertise spans pharmacogenomics, genomics, bioinformatics, oncology, biomedical informatics, and medication safety. Dr. Roosan's work focuses on pharmacogenomics, RNA expression effects, pathway deregulation in personalized drug response, implementation of complex genomics data into electronic health records, and consumer and clinical informatics. Her research program bridges computational biology, translational bioinformatics, and clinical pharmacy practice. Analysis of her 15 most recent publications reveals a consistent focus on pharmacogenomics implementation, cancer genomics, and biomedical informatics applications. Her work demonstrates strong interdisciplinary collaboration across computational biology, clinical pharmacy, and medical research, with publications spanning high-impact journals in bioinformatics, oncology, and pharmacology. National Library Medicine Post-Doctoral Fellowship (2012) Dr. Roosan has maintained an active research program while contributing to clinical pharmacy practice. Her professional experience includes work as a clinical pharmacist in acute care settings, clinical informatics director at a startup company, and implementation pharmacist with Cardinal Health Pharmacy Services serving 17 hospitals nationwide. Her research has resulted in publications in high-impact journals including Genome Medicine and Bioinformatics.
Isabelle Huys is a Professor at the Faculty of Pharmaceutical Sciences at KU Leuven. She serves as Vice-Rector for Research Policy and is affiliated with multiple institutes including the Center for IT & IP Law (CiTiP), KU Leuven Institute for Digital Society (DigiSoc), Institute for Rare Diseases (Leuven.IRD), Institute for Single Cell Omics (LISCO), and KU Leuven Cancer Institute (LKI). Research Focus : Regulatory sciences, market access for advanced therapies, rare diseases, biosimilar sustainability, and patient-centered decision-making frameworks. Leadership : Active in governance through roles in university councils, faculty boards, and research policy committees. Her recent publications analyze EU pharmaceutical legislation reforms, biosimilar market dynamics, and clinical trial eligibility criteria. She leads projects like INFORM-RD (patient-informed clinical platforms for rare diseases) and 3Dose (3D-printed drug delivery systems). Keywords: Clinical Pharmacology, Regulatory Affairs, Rare Diseases, Organoid Technology, Health Economics, Digital Health.
Torsten Risør is an Associate Professor at the Department of Public Health, Section of General Practice within the Faculty of Health and Medical Sciences at the University of Copenhagen. He concurrently serves as Associate Professor at the University of Tromsø – The Arctic University of Norway since 2010 and Senior Researcher at The Research Unit for General Practice since 2021. His work addresses systemic gaps between population healthcare needs and current public health system capacities through innovative futures-oriented research. His research centers on medical anthropology, medical education, general practice, leadership, and arctic health, utilizing the Prognosis framework which posits that future components exist in present practices. By analyzing healthcare education, clinical decision-making, and community innovation as historical trajectories, he develops scenarios for preferable healthcare futures. This approach shifts focus from static entity descriptions to movement, relations, and connectivity, requiring methodological evolution alongside thematic change. He maintains active international collaborations with professionals and students across Norway, Denmark, Canada, and Colombia. Recent publications (2024-2025) reveal three dominant research streams: medical education innovations (digital physical examination teaching, embodiment in professional development), emergency department dynamics (pharmacist integration impacts on nursing/physician workflows), and data utilization in general practice (clinical evaluation clusters). These studies predominantly employ qualitative, scoping review, and time-motion methodologies, highlighting context-sensitive solutions for complex healthcare challenges like aging populations, migration patterns, and climate change impacts. Risør's collaborative network spans multiple countries and disciplines, focusing on healthcare system adaptability. His work responds to widening gaps between population needs and healthcare capacities through strategic future-oriented research, emphasizing relational dynamics and contextual innovation rather than static problem-solving approaches.
Karen Curtin, PhD, MStat is an Associate Professor in the Department of Internal Medicine, Division of Epidemiology at the University of Utah School of Medicine and an adjunct Associate Professor in Ophthalmology and Visual Sciences at the John A. Moran Eye Center. She serves as Interim Director of the Utah Population Database (UPDB) at Huntsman Cancer Institute and is affiliated with the Pedigree and Population Resource. Dr. Curtin is a Huntsman Cancer Institute investigator in the Cancer Control and Population Sciences program and a Co-Investigator with the Steele Center for Translational Medicine at the Moran Eye Center. Dr. Curtin received her PhD in biomedical informatics with an emphasis in genetic epidemiology from the University of Utah, where she was awarded the John D. Morgan Fellowship Award in Biomedical Informatics. She completed post-doctoral training in molecular and risk factor epidemiology at Utah and holds an MStat degree. Before her academic career, she worked as a Master's level biostatistician on large population-based cancer studies. Her research focuses on genetic epidemiology and population-based science, with specific interests in gene-environment interactions, cancer epidemiology (particularly colorectal cancer), environmental pollution, epigenetics in cancer, and age-related macular degeneration with co-segregating diseases. She has developed expertise in using the Utah Population Database for population-based research on gastrointestinal cancers, breast density in relation to interval breast cancer, and genetic underpinnings of myeloid disorders. Her work often involves cross-disciplinary collaborations across University of Utah Health Sciences Center, Huntsman Cancer Institute, and Intermountain Healthcare. Dr. Curtin's recent publications show a strong focus on exfoliation syndrome and its systemic associations, colorectal cancer epidemiology, and genetic susceptibility to various cancers. Her research demonstrates consistent integration of population-based approaches with translational applications, particularly in ophthalmology and cancer prevention. Among her notable honors are the John D. Morgan Fellowship Award in Biomedical Informatics, an invitation to speak at the prestigious Lindberg Society Symposium at the 2018 World Ophthalmology Congress, and an award from the BrightFocus(R) Foundation's National Glaucoma Research Program to study prognostic factors in exfoliation glaucoma. As Interim Director of the Utah Population Database, Dr. Curtin oversees a resource supporting over 290 active research projects. She collaborates extensively with investigators across multiple disciplines, particularly in cancer epidemiology, ophthalmology, and population health. Her research infrastructure expertise has led to productive collaborations with translational and clinical investigators in age-related macular degeneration, exfoliation syndrome/glaucoma, and gastrointestinal cancers. Dr. Curtin maintains active laboratory research through the Curtin Group, which utilizes the Utah Population Database linked to University of Utah and Intermountain Healthcare records, including complex radiology and pharmacy data, to study cancer epigenetics and epidemiology across multiple disease domains.
Dr. Ahmad S. Halwani serves as an Associate Professor of Medicine in the Division of Hematology and Hematologic Malignancies within the Department of Internal Medicine at the University of Utah School of Medicine. He concurrently holds positions as a staff physician and health services researcher at the Informatics, Decision Enhancement, & Analytics Sciences (IDEAS) Center of Innovation at the George E Whalen Veterans Administration Medical Center in Salt Lake City. His dual appointments bridge academic medicine and Veterans Affairs healthcare systems, with specialized roles as cancer data subject matter expert and health information technology implementation expert for the VA National Oncology Program. His educational background includes a Medical Degree (M.D.) and Bachelor of Science in Biology with High Distinction from the American University of Beirut. He completed residency training in Internal Medicine followed by fellowships in Medical Oncology and Allergy and Immunology at the University of Iowa Hospitals & Clinics. His board certifications encompass the American Board of Internal Medicine (Medical Oncology sub-specialty) and the Educational Commission for Foreign Medical Graduates. Dr. Halwani's research program centers on leveraging electronic health record (EHR) data to develop clinical decision support tools, analytics platforms, and user interfaces that optimize provider workflows while enhancing care quality, safety, and effectiveness. His work pioneers novel tele-oncology care models and applies advanced computational methods including deep learning and generative large language models to cancer care delivery systems. Key research domains include EHR-based cancer registry development, symptom assessment system implementation, and medication management for oral anticancer therapies. His publication portfolio reveals strong emphasis on Veterans' cancer care with recurring themes in lymphoma management, health disparities analysis, and health information technology implementation. Recent work demonstrates increasing integration of artificial intelligence methodologies within clinical oncology workflows, particularly through EHR data extraction and real-time decision support applications. University of Utah VP Clinical and Translational Scholar (2016) NCI Cancer Clinical Investigator Team Leadership Awardee (2018) National Comprehensive Cancer Network panel member for cutaneous and T-cell lymphoma guidelines As a health services researcher at the VA IDEAS Center, Dr. Halwani leads data analytics initiatives supporting multiple national VA oncology programs including the Breast and Gynecological Cancer System of Excellence, Cancer Care Navigation and Tracking, and Clinical Trial Navigation Center. His work has directly informed congressional reports on Veterans' access to genetic testing and shaped national implementation of symptom assessment systems. He maintains active roles in clinical trial methodology development and serves as subject matter expert for VA oncology informatics infrastructure. His laboratory affiliations include the Division of Epidemiology and VERITAS research group, focusing on translational applications of health informatics in cancer care delivery systems. Current projects involve developing EHR-integrated patient-reported outcome tools and optimizing medication safety systems for oral anticancer therapies within the Veterans Health Administration.
